DS
AXSM icon

David Shaw’s Axsome Therapeutics AXSM Stock Holding History

David Shaw’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148M Buy
604,753
+1,288
+0.2% +$279K 0.07% 296
2026
Q1 		$102M Buy
603,465
+54,352
+10% +$9.39M 0.06% 373
2025
Q4 		$100M Buy
549,113
+252,826
+85% +$35.3M 0.06% 401
2025
Q3 		$36M Buy
296,287
+95,523
+48% +$10.8M 0.02% 823
2025
Q2 		$21M Sell
200,764
-346,901
-63% -$36.7M 0.01% 1007
2025
Q1 		$63.9M Buy
547,665
+527,319
+2,592% +$60.1M 0.06% 402
2024
Q4 		$1.72M Buy
20,346
+17,446
+602% +$1.6M ﹤0.01% 2835
2024
Q3 		$261K Sell
2,900
-3,434
-54% -$300K ﹤0.01% 4045
2024
Q2 		$510K Sell
6,334
-1,435
-18% -$106K ﹤0.01% 3609
2024
Q1 		$620K Sell
7,769
-1,415
-15% -$119K ﹤0.01% 3379
2023
Q4 		$731K Buy
+9,184
New +$614K ﹤0.01% 3337
2022
Q3 		– Sell
-6,762
Closed -$259K – 5179
2022
Q2 		$259K Sell
6,762
-148,630
-96% -$4.7M ﹤0.01% 4421
2022
Q1 		$6.43M Buy
+155,392
New +$4.82M 0.01% 2034
2021
Q4 		– Sell
-13,939
Closed -$513K – 5391
2021
Q3 		$459K Sell
13,939
-9,110
-40% -$355K ﹤0.01% 4140
2021
Q2 		$1.55M Sell
23,049
-10,169
-31% -$610K ﹤0.01% 3179
2021
Q1 		$1.88M Sell
33,218
-133,964
-80% -$9.42M ﹤0.01% 2645
2020
Q4 		$13.6M Sell
167,182
-64,060
-28% -$4.79M 0.01% 1185
2020
Q3 		$16.5M Sell
231,242
-4,461
-2% -$348K 0.02% 944
2020
Q2 		$19.4M Sell
235,703
-122,992
-34% -$9.47M 0.02% 795
2020
Q1 		$21.1M Buy
358,695
+275,232
+330% +$22.4M 0.03% 593
2019
Q4 		$8.63M Sell
83,463
-36,488
-30% -$1.47M 0.01% 1313
2019
Q3 		$2.43M Buy
119,951
+85,195
+245% +$2.19M ﹤0.01% 2214
2019
Q2 		$895K Buy
+34,756
New +$697K ﹤0.01% 2741

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's AXSM Position: Q2 2026 in Review

David Shaw increased its Axsome Therapeutics (AXSM) stake by 0.21% in Q2 2026, buying an estimated $279K and bringing the position to 604,753 shares worth $148M. The position accounts for 0.07% of the portfolio, ranked #296.

David Shaw first reported a position in AXSM in Q2 2019 and has held it in 23 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • David Shaw held 604,753 shares of Axsome Therapeutics worth $148M as of Q2 2026.
  • David Shaw bought 1,288 Axsome Therapeutics shares in Q2 2026, an estimated $279K.
  • Axsome Therapeutics made up 0.07% of David Shaw's portfolio in Q2 2026, its #296 holding.
  • David Shaw first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.